| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Executive Officer
1 company
Punit Dhillon is Chief Executive Officer at SKYE. Punit Dhillon's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.7M at current prices.
Net of sales, the SKYE filings show accumulation of 798,090 shares.
Punit Dhillon has 12 Form 4 filings on record from December 2021 to August 2026, all as Chief Executive Officer at Skye Bioscience (SKYE), 2021–2026.
The 38 reported transactions were 18 option or other derivative awards, 7 stock awards, 7 dispositions back to the company and 2 open-market sales, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $16K and 1 sale worth about $414K.
The only open-market purchase was 881,000 shares of SKYE at an average $0.02 on August 29, 2023, about $16K.
The only open-market sale was 82,910 shares of SKYE at an average $4.99 on November 18, 2024, about $414K. Twelve months later SKYE was down 71%.